Miow, Quig, Vallejo Pulido, Andres, Wang, Yu, Hong, Jia, Bai, Chen, Teo, Felicia, Wang, Alvin, Loh, Hong, Tan, Tuan, Ding, Ying, She, Hoi, Gan, Suay, Paton, Nicholas, Lum, Josephine, Tay, Alicia, Chee, Cynthia, Tambyah, Paul, Polak, Marta, Wang, Yee, Singhal, Amit, Elkington, Paul, Friedland, Jon S. and Ong, Catherine W.M. (2021) Doxycycline host-directed therapy in human pulmonary tuberculosis. Journal of Clinical Investigation, 131 (15), [e14i895]. (doi:10.1172/JCI141895).
Abstract
BACKGROUND. Matrix metalloproteinases (MMPs) are key regulators of tissue destruction in tuberculosis (TB) and may be targets for host-directed therapy. We conducted a phase II double-blind, randomized, controlled trial investigating doxycycline, a licensed broad-spectrum MMP inhibitor, in patients with pulmonary TB. METHODS. Thirty patients with pulmonary TB were enrolled within 7 days of initiating anti-TB treatment and randomly assigned to receive either 100 mg doxycycline or placebo twice a day for 14 days, in addition to standard care. RESULTS. Whole blood RNA-sequencing demonstrated that doxycycline accelerated restoration of dysregulated gene expression in TB towards normality, rapidly down-regulating type I and II interferon and innate immune response genes, and up-regulating B-cell modules relative to placebo. The effects persisted for 6 weeks after doxycycline discontinuation, concurrent with suppressed plasma MMP-1. Doxycycline significantly reduced sputum MMP-1, -8, -9, -12 and -13, suppressed type I collagen and elastin destruction, reduced pulmonary cavity volume without altering sputum mycobacterial loads, and was safe. CONCLUSION. Adjunctive doxycycline with standard anti-TB treatment suppressed pathological MMPs in PTB patients. Larger studies on adjunctive doxycycline to limit TB immunopathology are merited.
More information
Identifiers
Catalogue record
Export record
Altmetrics
Contributors
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.